Comparison · NCT02786277-52bacb87
Recommended vs Anti-recommended: Progression to Stage 3 AKI
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Recommended vs Anti-recommended: Progression to Stage 3 AKI. Trial comparisons, record NCT02786277-52bacb87. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02786277-52bacb87
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0719 | 0.0574 | 0.0895 | wilson | |
| Risk in group 2 | 0.0632 | 0.05 | 0.0796 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00864 | -0.0132 | 0.0307 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.14 | 0.823 | 1.57 | log | |
| Odds ratio, group 1 over group 2 | 1.15 | 0.812 | 1.62 | log | |
| Number needed to treat, for one more participant with the outcome on Recommended than on Anti-recommended | 116 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Recommended | Those whose uplift score represents a probability of benefit greater than 0.5 will generate an alert, while those whose uplift score represents a probability of benefit less than 0.5 will not generate an alert.~Alert: An alert informing the provider of the presence of acute kidney injury will be fired. | 72 | 1,002 | OG000 |
| Group 2 | Anti-recommended | Those whose uplift score represents a probability of benefit greater than 0.5 will not generate an alert, while those whose uplift score represents a probability of benefit less than 0.5 will generate an alert.~Alert: An alert informing the provider of the presence of acute kidney injury will be fired. | 66 | 1,044 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Progression to Stage 3 AKI
- Description
- Progression to Stage 3 AKI is defined as a tripling of serum creatinine between the date of randomization and 14 days post randomization, and is considered a worsening of AKI.
- Time frame
- Assessed from the date of randomization to 14 days post randomization
- Population
Source ClinicalTrials.gov
Trial
- Title
- Learning Alerts for Acute Kidney Injury
- NCT number
- NCT02786277
- Phases
- NA
- Conditions
- Acute Kidney Injury
- Interventions
- Alert
- Lead sponsor
- Yale University
- Results first posted
- 2025-10-08
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02786277?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02786277-52bacb87